Li Zhu
- Oncology top 5%
- Cancer Research top 5%
- Molecular Biology
- Pulmonary and Respiratory Medicine top 10%
- Surgery top 10%
- Topics
- Breast Cancer Treatment Studies (43 papers)HER2/EGFR in Cancer Research (28 papers)Breast Lesions and Carcinomas (15 papers)
- Journals
- Journal of Clinical OncologySHILAP Revista de lepidopterologíaBlood
- Partner nations
- ChinaUnited StatesCanada
In The Last Decade
Li Zhu
119 papers receiving 1.9k citations
Hit Papers
Peers
Comparison fields: 5 of 106
- Oncology 792
- Cancer Research 634
- Molecular Biology 553
- Pulmonary and Respiratory Medicine 373
- Surgery 304
Countries citing papers authored by Li Zhu
This map shows the geographic impact of Li Zhu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Li Zhu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Li Zhu more than expected).
Fields of papers citing papers by Li Zhu
This network shows the impact of papers produced by Li Zhu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Li Zhu. The network helps show where Li Zhu may publish in the future.
Co-authorship network of co-authors of Li Zhu
This figure shows the co-authorship network connecting the top 25 collaborators of Li Zhu. A scholar is included among the top collaborators of Li Zhu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Li Zhu. Li Zhu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 2 | |
| 2 | 4 | |
| 3 | 8 | |
| 4 | 3 | |
| 5 | Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinomabreakdown → | 161 |
| 6 | 24 | |
| 7 | 41 | |
| 8 | 1 | |
| 9 | 3 | |
| 10 | 12 | |
| 11 | 7 | |
| 12 | 7 | |
| 13 | 49 | |
| 14 | 14 | |
| 15 | 9 | |
| 16 | 26 | |
| 17 | 51 | |
| 18 | 1 | |
| 19 | HER2 and topoisomerase IIalpha: possible predictors of response to neoadjuvant chemotherapy for breast cancer patients. | 10 |
| 20 | Changes of Antimicrobial Resistance of E.coli | 1 |
About Li Zhu
Li Zhu is a scholar working on Cancer Research, Oncology and Pathology and Forensic Medicine, having authored 124 papers that have together received 2.0k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (43 papers), HER2/EGFR in Cancer Research (28 papers) and Breast Lesions and Carcinomas (15 papers). The work is most often cited by research in Cancer Research (634 citations), Oncology (792 citations) and Biological Psychiatry (56 citations). Li Zhu has collaborated with scholars based in China, United States and Canada. Frequent co-authors include Kunwei Shen, Jiayi Wu, Weiguo Chen, Yafen Li, Ou Huang, Xiaosong Chen, Jianrong He, Xiaochun Fei, Na Li and Qunying Han. Their work appears in journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.